Sign in

CIK 0001840233

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Xilio Therapeutics, Inc.

Sign in to watch
Ticker
XLO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
851623397
Phone
+1 617-833-1027
Business address
828 WINTER STREET, WALTHAM, MA, 02451
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2021-10-26 RiverVest Venture Fund IV, L.P. 10% owner Purchase +250,000 $16.00 $4.0M 1,441,444
2021-10-26 RiverVest Venture Fund IV, L.P. 10% owner Conversion · Series B Preferred Stock −832,120 0
2021-10-26 RiverVest Venture Fund IV, L.P. 10% owner Conversion · Series B Preferred Stock −359,324 0
2021-10-21 Russo Rene CEO and President Grant or award · Stock Option (right to buy) +50,041 50,041
2021-10-21 Ross Michael Jay Director Grant or award · Stock Option (right to buy) +26,400 26,400
2021-10-21 Huber Martin H. Jr. President of R&D and CMO Grant or award · Stock Option (right to buy) +157,058 157,058
2021-10-21 Giovine Salvatore Chief Financial Officer Grant or award · Stock Option (right to buy) +28,755 28,755

Page 13 of 13 · 247 trades